EFFECTS OF LOSARTAN ON BLOOD PRESSURE AND MICROALBUMINUREA IN HYPERTENSIVE TYPE 2 DIABETIC PATIENTS

Diabetic nephropathy and hypertension are the leading causes of mortalitiy and morbidity in diabetes mellitus type 2 patients. Blockage of renin-angiotensin system with ACE inhibitors, retard the progression of diabetic nephropathy. The aim of this study was to determine the antihypertensive and antimicroalbuminuric effects of losartan in type 2 diabetic and hypertensive patients. 17 diabetics (7 female and JO male, aged 54.8±5.46 ) with hypertension were treated with 50mg/daily of losartan for 12 weeks and followed for the changes in systemic arterial blood pressure, microalbuminuriea and blood biochemistry. Microalbuminuriea decreased to 19.3±2.7mg/dayfrom 5I.4±4.3mg/day (p<0.005) after treatment. Systolic pressure decreased to 132.2±11.4mmHgfwm 156±J5.4 mmHg (p< 0.05) and diastolic pressure decreased to 70.8±15.2 mmHg from 89.3±12.4 mmHg (p< 0.005). Fasting blood glucose , lipids, urea, creatine, derence of creatine and uric acid were not effected unfavourably. In conclusion, losartan reduces blood pressure and microalbuminurea but does not effect the blood biochemistry in hypertensive type II diabetic patients.